Ancilia develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. Our approach harnesses the natural function of CRISPR to enhance bacterial immunity against viruses and effectively modulate the human microbiome.
Location: United States, New York
Employees: 1-10
Founded date: 2019
Investors 2
| Date | Name | Website |
| 25.04.2023 | Metaplanet... | metaplanet... |
| - | Bioverge | ventures.b... |
Mentions in press and media 1
| Date | Title | Description | Source |
| - | Ancilia Biosciences | “A CRISPR route to success for live biotherapeutics & bacterial products” | fastfounde... |